DATRON AG (DAR.DE)
Chart Events
Performance Outlook
| Previous Close | 11.00 |
| Open | 11.20 |
| Bid | 11.00 x 50000 |
| Ask | 11.40 x 135400 |
| Day's Range | 11.00 - 11.20 |
| 52 Week Range | 10.40 - 13.20 |
| Volume | |
| Avg. Volume | 504 |
| Market Cap | 43.827M |
| Beta (5Y Monthly) | 0.93 |
| PE Ratio (TTM) | 15.07 |
| EPS (TTM) | 0.73 |
| Earnings Date | Nov 04, 2021 |
| Forward Dividend & Yield | 0.05 (0.40%) |
| Ex-Dividend Date | Jun 28, 2021 |
| 1y Target Est | 15.40 |
- Business Wire
GenSight Biologics: Annual General Meeting on May 25, 2022
PARIS, May 04, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 25, 2022, at 9:00 am CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France (*).
- Business Wire
GenSight Biologics Granted Six-Month Extension in LUMEVOQ® European Regulatory Review
PARIS, April 14, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA) has granted the Company a six-month extension for submitting its responses to the Day 120 questions in the regulator
